Binx key facts
as of Oct 2026- Developer of a point-of-care testing platform designed to improve the well-being of communities by providing pathways to care that prioritize clinical integrity and patient convenience.
- Binx is valued at approximately $333.9M as of Oct 2026 (last reported valuation).
- It has raised $279.5M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Innovate UK, OrbiMed, Johnson & Johnson JJDC, EQT Life Sciences, Novartis Venture Fund — 21 tracked in total.
- Status: Privately Held (backing).
Binx's last reported valuation, May 2021. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Binx: the Monday email on marks, rounds and moves
Binx funding rounds
No funding rounds for Binx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Binx
21+Binx valuation
Binx's last reported valuation was $334 million in May 2021. No priced round, secondary trade or fund mark has surfaced since.
Binx investors
21 investors are on record for Binx, including Innovate UK, OrbiMed, Johnson & Johnson JJDC and EQT Life Sciences.
About Binx
Developer of a point-of-care testing platform designed to improve the well-being of communities by providing pathways to care that prioritize clinical integrity and patient convenience. The company's platform offers rapid polymerase chain reaction (PCR)-based results as well as provides a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up to increase screening and reduce infections, enabling people to get accurate diagnostic reports through discreet testing.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2005
- Employees
- 91
- Website
- mybinxhealth.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.